Consideration of the cathinones. by unknown
ACMD 
Advisory Council on the Misuse of Drugs 
 
 
 
Consideration of the cathinones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 1 of 50  
ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor Les Iversen 
Secretary: Will Reynolds 
 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
Tel: 020 7035 0454  
ACMD@homeoffice.gsi.gov.uk
 
Rt Hon Alan Johnson MP 
2 Marsham Street 
London  
SW1P 4DF 
31st March 2010 
 
Dear Home Secretary,  
 
I have pleasure in attaching the Advisory Council on the Misuse of Drugs 
report on the ‘Consideration of the cathinones’.  
 
The ACMD recommends that the cathinone compounds be brought under 
control of the Misuse of Drugs Act 1971 in Class B, Schedule I by way of a 
generic definition. Based on the attached evidence and by analogy with the 
amphetamines, the ACMD consider that the harms associated with the 
cathinones most closely equate with other compounds in Class B.  
 
The ACMD also recommend that particular attention is focussed on credible 
and consistent public health messages that are promulgated both to the public 
and health professionals – the latter for the purposes of providing advice.  
 
The ACMD is concerned that, particularly in the case of mephedrone, the 
internet plays a significant part in the marketing, sale and distribution of the 
drug and social networking sites may also play a role. The ACMD therefore 
believes that resources should initially be focussed on supply side activities 
with a concurrent emphasis on educating users of this drug so as to highlight 
the real dangers of mephedrone and the cathinones.    
 
The ACMD indicated, in its letter to the Home Secretary, of the 22nd 
December 2009, its concerns about the sale of mephedrone and its plans for 
review. However, the rapid increase in the use of mephedrone in the UK has 
been exceptional. This sudden rise in prevalence of what we consider to be a 
harmful drug has brought to the fore our concerns that we need to consider a 
range of options for limiting the rapid spread of such substances. The ACMD 
intend to provide you with further advice on the possible control of ‘legal highs’ 
concerning recommendations and advice that is broader than the scope of 
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what either this report or that on other individual or classes of compounds will 
allow.  
 
In addition, I would like to draw your attention to further advice that we will 
provide on the napthyl analogues of pyrovalerone and other such analogues. 
The ACMD will meet to discuss other compounds that are not covered by this 
generic scope in the next few weeks.  
 
 
Yours faithfully, 
 
 
Professor Les Iversen FRS 
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1. Background 
1.1. In March 2009 the then Home Secretary requested advice from the 
ACMD on so called ‘legal highs’. The ACMD have looked at a number of 
substances to date and provided advice on the piperazines and the 
synthetic cannabinoids (‘Spice). The ACMD wrote to the Home Secretary 
in December 2009 (Annex D) setting out the ACMD’s concerns regarding 
the cathinones and mephedrone in particular, which first came to the 
ACMDs attention in the summer of 2009. On the 2nd February 2010 the 
ACMD Chair (Professor Les Iversen) met with the Home Secretary to 
further discuss the issue and to provide an update.   
 
1.2. The ACMD gathered evidence on the cathinones at a special meeting of 
the Technical Committee (22nd February 2010) and discussed additional 
evidence and possible recommendations at a further Technical Committee 
meeting on the 25th March 2010, and at the ACMD Council meeting on the 
29th of March 2010.   
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2. Introduction 
2.1. Cathinone is one of a number of alkaloids which can be extracted from 
the (fresh) leaves of Catha edulis (khat). It is structurally very similar to 
amphetamine (1-phenylpropan-2-amine) and represents the β-keto 
analogue of amphetamine. 
 
2.2. Cathinone (Class C), methcathinone (Class B), diethylpropion (Class 
C) and pyrovalerone (Class C) are controlled under the Misuse of Drugs 
Act 1971. The three controlled cathinone derivatives are listed in the 
United Nations Convention on Psychotropic Substances (1971) and have 
been reveiwed by the WHO Expert Committee on Drug Dependence 
(WHO, 1995).  However, other derivatives and analogues are not 
presently controlled (including mephedrone). Notwithstanding the potential 
harms of the cathinones it is apparent that mephedrone and other 
cathinones are being sold without any apparent effective regulation.   
 
2.3. The ACMD has communicated its intentions to review the cathinones 
to the Home Secretary, over recent months, through meetings and 
correspondence (see the ACMD’s letter of the 22nd Dec 2009 – Annex D). 
The ACMD has been concerned about the rise in prevalence of the 
cathinones and potential harms initially through reports from drug services, 
young people’s treatment services, head teachers, drug surveys, the 
police and media, among others.  
 
2.4. Other countries (including: Sweden Denmark, Norway, Ireland and 
Israel) have recently controlled specific cathinones. However, we are not 
aware of any country that has developed generic legislation to control the 
cathinones as a class.  
 
2.5. The ACMD is aware of the collation of data on mephedrone by Europol 
and the EMCDDA in the form of a joint report under Article 5.1 of Council 
Decision 2005/387/JHA. The ACMD wrote to the UK focal point (the Reitox 
NFP) that would be providing information as requested by Article 5 of the 
Decision.   
 
2.6. This report is compiled from oral and written evidence considered at the 
meetings (paragraph 2.3) above. A full citation of the evidence received 
and considered is provided in Section 10 and submitting individuals and 
organisations are given in Annex C.  
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3. Chemistry and pharmacology 
 
Chemistry1
3.1. Cathinone (2-amino-1-phenyl propanone) is one of a number of 
alkaloids which can be extracted from the (fresh) leaves of Catha edulis 
(khat). However, the ACMD understands that most of the cathinones 
seized, and those that have been tested, are synthetic in origin.  
 
3.2. Cathinone is structurally very similar to amphetamine (1-phenylpropan-
2-amine), differing only in the functionality present at the β-carbon. 
Cathinone possesses a ketone oxygen at the β-carbon; cathinone can 
therefore be considered as the ‘β-keto analogue’ of amphetamine (see 
Figures 1 and 2).  
 
Figure 1: The structural similarity between amphetamine (left) and cathinone 
(right) 
 
 
 
 
 
3.3. Structural modifications to the 1-phenylpropan-2-amine (amphetamine) 
backbone have produced a range of different compounds, many of which 
are closely related structurally to amphetamine; these are known as the 
‘amphetamines’. In a similar manner, the molecular architecture of 2-
amino-1-phenyl propanone (cathinone) can be altered to produce a series 
of different compounds which are closely structurally related to cathinone. 
Together these are known as the ‘cathinones’ or ‘cathinone derivatives’. 
 
3.4. The N-methyl derivative known as methcathinone or ephedrone is the 
cathinone analogue of methylamphetamine, while 3,4-methylene-
dioxymethcathinone (methylone) is the cathinone analogue of MDMA 
(ecstasy); 4-methylmethcathinone (mephedrone) has no commonly used 
amphetamine equivalent. 
 
3.5. The basic cathinone structure (see Figure 2) can be altered in a number 
of predictable ways, such as the inclusion of additional functionality to the 
aromatic ring (ring substitution, R4), N-alkylation (or inclusion of the 
nitrogen atom in a ring structure, R2 and R3), and variation of the (typically 
alkyl) α-carbon substituent (R1). Multiple modifications may of course be 
present in a single derivative; cathinones are all usually N-alkylated (or the 
nitrogen is incorporated into a ring structure, typically pyrrolidine) and 
many also bear ring substituents. 
 
 
 
                                                 
1 White, 2010. 
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Figure 2: Generic sites for structural variation of cathinone, detailing α and β 
positions2. 
 
 
 
 
 
 
 
 
 
3.6. The genesis of synthetic cathinone chemistry is rooted in the synthesis 
of cathinone over 120 years ago. Since this time, many synthetic 
cathinones have been reported, the vast majority of which have not been 
used in a medicinal setting. However, a handful of cathinones, such as 
diethylpropion, bupropion and pyrovalerone have been used in 
pharmaceutical preparations, and the properties of novel cathinones (such 
as napthylpyrovalerone (Meltzer et al., 2006)) is still an area of active 
research. 
 
3.7. Bupropion (page 42) is used medically as an antidepressant and an aid 
to smoking cessation and is a prescribed drug, marketed under the trade 
name Zyban®. Although it is a ring substituted cathinone no samples of 
Bupropion have been encountered in forensic analysis of seizures in the 
UK, and there is no evidence for its misuse.  
 
3.8. The misuse of selected synthetic cathinones is not new; methcathinone 
(ephedrone), originally used as an antidepressant in the former Soviet 
Union in the 1930’s, went on to be used recreationally there (especially 
during the 1970s and 1980s) and in the USA (1990s). The emergence of 
six synthetic cathinones in Germany was reported between 1997 and 
2004. All six substances bear an α-pyrrolidino functionality and are 
therefore closely related to pyrovalerone (page 41).  
 
3.9. More recently, there have been an increasing number of reports of other 
synthetic cathinones encountered within the European Union. Although 
many of these compounds are simply β-keto analogues of well-known 
amphetamines, the presence of the ketone functionality often circumvents 
any control measures which may already be in place for the related 
                                                 
2 The generic cathinone backbone (see Figure 2) possesses a chiral centre (the α-carbon 
atom if R1≠H); cathinone and its derivatives can therefore exist as stereoisomers, the 
potencies of which may be markedly different. Although it is the S-enantiomer of cathinone 
which is found in the fresh leaves of Catha edulis, the chirality of the cathinones is not 
determined during routine forensic analysis of seizures. There is, however, no evidence to 
suggest that the synthetic cathinones currently available are enantiopure; it is instead likely 
that they are supplied as racemic mixtures. The qualitative or quantitative differences 
between the enantiomers of the non-controlled cathinones is not known. 
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amphetamine congeners. Since 2006, the following cathinones have been 
reported in the European Union (see Table 1; for the position of the 
substituents R1 to R4, see Figure 2). According to data from UK forensic 
providers, since January 2006 six of these have been encountered in the 
UK (emboldened in Table 1). 
 
 Table 1: Some of the non-controlled cathinones encountered in the 
European Union since 2006 (excluding reports of pyrovalerone derivatives 
from 1997-2004). those in bold type have been encountered in the UK.  
 
Name Common name R1 R2 R3 R4
N,N-dimethylcathinone   Me Me Me H 
Ethcathinone   Me Et H H 
4-Methylmethcathinone Mephedrone Me Me H 4-Me 
Bk-PMMA Methedrone  Me Me H 4-MeO 
4-Fluoromethcathinone Flephedrone  Me Me H 4-F 
3-Fluoromethcathinone   Me Me H 3-F 
bk-MDMA Methylone  Me Me H 3,4-methylenedioxy 
bk-MDEA  Ethylone Me Et H 3,4-methylenedioxy 
bk-MBDB  Butylone Et Me H 3,4-methylenedioxy 
MDPV Methylenedioxypyrovalerone n-Pr pyrrolidinyl 3,4-methylenedioxy
 
3.10. Of the total number of cathinone derivatives encountered by UK forensic 
providers, by far the most commonly encountered is 4-
methylmethcathinone (mephedrone) (89% of seizures). However, data 
from the Forensic Science Service indicate that cathinones accounted for 
a very small fraction of Police seizures submitted in 2009. Tentative data 
also indicate a rapid rise in the number of cathinone submissions during 
2009, with a concomitant decrease in the number of piperazine 
submissions. 
 
3.11. Data from UK forensic providers suggest that the cathinones are 
normally submitted as either white or brown powders3; data from January 
2006 to mid-February 2010 indicate that, of all cathinone derivatives 
submitted, 95% were in powder form, 4% being submitted as tablets or 
capsules.  
 
3.12. Purity data for the cathinones are not available from UK forensic 
providers, since it is not usually determined during routine forensic 
analysis. However, cathinones are normally advertised as being of ‘high 
purity’, typically >95%. Some adulterants, including benzocaine, 
lignocaine, caffeine and paracetamol, have been detected in a small 
proportion of seizures of the cathinones. Some submissions have been 
adulterated with controlled drugs such as cocaine, ketamine, 
amphetamine and 1-benzylpiperazine (BZP), although these are rarely 
encountered.  
 
                                                 
3 The freebase forms of the cathinones are unstable and readily decompose; the cathinones 
are normally encountered as the hydrochloride salts. 
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3.13. There are currently no colorimetric field tests available to identify all of 
the cathinone derivatives, although some chemical tests, such as the 
Simon’s test and Chen test may be used to give an indication of the 
presence of a small number of the cathinones.  More specific field tests 
based on immunoassay technology are not yet available4. 
 
3.14. As with the amphetamines, both systematic (IUPAC) and non-standard 
nomenclature is common in cathinone chemistry. Often, the assimilation of 
a common structural motif is reflected in non-standard nomenclature. 
Thus, structural incorporation of the ‘2-methylamino-1-phenyl-1-
propanone’ fragment, which is also known as methcathinone or 
‘ephedrone’, is often indicated in nomenclature; 4-methylmethcathinone is 
‘mephedrone’ and 4-fluoromethcathinone is ‘flephedrone’. The use of 
acronyms is also widespread; 3,4-methylenedioxypyrovalerone is known 
as ‘MDPV’, whilst α-pyrrolidinopropiophenone, one of a number of α-
pyrrolidino cathinones, is simply known as α-PPP. As a consequence of 
the β-keto substituent, it is also common practice for widely accepted 
amphetamine acronyms to be augmented with the prefix ‘bk’. For example, 
3,4-methylenedioxymethcathinone (methylone), the cathinone analogue of 
MDMA, is often referred to as ‘bk-MDMA’.  Mephedrone [2-(methylamino)-
1-(4-methylphenyl)-1-propanone] is the most commonly used cathinone 
derivative and forms the focus of this report. 
 
Pharmacology 
3.15. As with the amphetamines, the cathinones act as central nervous 
system stimulants, although the potencies of the cathinones are generally 
lower then their amphetamine congeners, probably because the increased 
polarity conferred on a cathinone by the presence of a β-keto group 
reduces their ability to cross the blood-brain barrier. 
 
3.16. Several cathinones have been used as active pharmaceutical 
ingredients (API). Bupropion has been used as an antidepressant, and as 
an aid to stop smoking cigarettes. Diethylpropion (Amfepramone) and 
pyrovalerone have both been proposed as appetite suppressants, 
although they are not currently in clinical use. 4-methylmethcathinone 
(mephedrone), the most commonly encountered synthetic cathinone 
derivative in the UK, has never been used as an API or patented as a 
potential API. 
 
3.17. Little data are available on either the pharmacokinetics or 
pharmacodynamics of the cathinones. Research on the metabolism of the 
ring-substituted cathinones bk-MBDB and bk-MDEA has implicated N-
dealkylation, demethylenation followed by O-methylation and β-keto 
reduction as major metabolic pathways (Zaitsu et al., 2009).  
 
                                                 
4 Colorimetric tests based on the Marquis reaction cannot be used to identify all of the 
cathinone derivatives. Some chemical tests, such as the Simon’s test and Chen test may be 
used to give an indication of the presence of a small number of the cathinones. 
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3.18. The effects of cathinones bearing ring-substituents in human subjects 
are reportedly similar to those of cocaine, amphetamine and MDMA (Table 
2; CairScotland, 2010). Self reported subjective effects of ring-substituted 
cathinones include:  
• Feelings of empathy (openness, love, closeness, sociability, well-
being); 
• Stimulation / alertness / rushing;  
• Euphoria / mood lift / appreciation of music; and,  
• Awareness of senses. 
 
3.19. Studies of the effects of cathinones on monoamine neurotransmission 
in rat brain confirm their mechanisms of action to be similar to those of the 
amphetamines. Both groups of drugs bind to monoamine transporters for 
dopamine, serotonin and noradrenaline (norepinephrine) in brain and 
promote release of these monoamines (Cozzi et al., 1999; Nagai et al., 
2007). As with the different amphetamines, individual cathinone 
derivatives vary in their relative potencies as inhibitors of the three 
monoamine transporters – summarised in Table 2. There are no published 
data on the effects of mephedrone on monoamine transporters, but it may 
be expected to be intermediate in its profile between methcathinone and 
methylone.  
 
Table 2. Actions of selected drugs on monoamine transporters* 
 
 Dopamine Serotonin Noradrenaline 
Amphetamine +++ + ++++ 
MDMA ++ +++ +++ 
Cathinone +++ ++ +++ 
Methcathinone +++ + +++ 
Methylone ++ +++ ++++ 
Mephedrone ? ? ? 
 
*Data from Cozzi et al., (1999) and Nagai et al., (2007). Values are depicted as 
relative affinities since the studies did not use the same units. + = low affinity; ++++ = 
highest affinity.  
 
3.20. It is notable that the cathinones examined were potent inhibitors of the 
noradrenaline (norepinephrine) transporter (NET). This helps to explain 
the strong sympathomimetic5 actions of cathinones – due to their ability to 
promote release of noradrenaline from the sympathetic nerves in various 
peripheral organs, notably the heart and vascular system.  
 
3.21. Cathinone and methcathinone are amphetamine-like behavioural 
stimulants. When administered to experimental animals they cause 
hyperactivity, with methcathinone being approximately 10 times more 
potent than cathinone (Feyissa and Kelly, 2008; Glennon et al., 1987) 
 
                                                 
5 mimicking stimulation of the sympathetic nervous system 
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3.22. When administered in vivo to rats trained to recognise and to 
distinguish the subjective effects of amphetamine, the animals cross-
generalised completely to methcathinone (i.e. they were unable to 
recognise this substances as having different effects from amphetamine). 
Methylone, however, showed only weak cross generalization to 
amphetamine, but cross generalized completely to MDMA in rats trained to 
recognize this as the discriminative stimulus (Dal Cason et al.,1997).  
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4. Epidemiology of cathinone use and methods of use 
 
Availability and use 
4.1. Many of the cathinone compounds, particularly mephedrone, can be 
purchased from many different sources, and are readily available over the 
internet. Although the provenance of the substances is often not clear, 
several suppliers source compounds from China (Ramsey, 2010; UK 
Border Agency, 2010). Exercises at Heathrow targeting air courier traffic 
from China for delivery to UK domestic addresses gave rise to seizures of 
mephedrone. Claims of manufacture in a number of other countries are 
made on the internet.  
 
4.2. Intelligence from Australia Customs and Border Protection Service has 
identified China and the UK as being the principal source of mephedrone. 
However, it is likely that in the case of the UK, this represents transit of the 
drugs and not necessarily production in the apparent country of origin. 
 
4.3. Mephedrone and other cathinones are predominantly sold over the 
internet and in ‘head shops’. Websites selling cathinone based compounds 
– generally mephedrone - normally exhibit a disclaimer that the 
compounds ‘are not for human consumption’. Instead, they are sold as 
research chemicals, ‘novelty bath salts’ (3-fluoromethcathinone) or, more 
commonly, as plant food/plant growth regulators (Sumnall, 2009). 
However, none of the cathinones has any recognized efficacy as a plant 
fertilizer nor would they suitably function as bath salts.  
 
4.4. Slang terms for some of the cathinones include Bubble(s), miaow, meow 
meow, 4-MMC, Mcat, sub-coca, toot and Top Cat.  
 
4.5. Cathinones (generally mephedrone) are usually sold as white or brown 
powders, sometimes as capsules, or more rarely as pills, and are often 
advertised as being of ‘high’ purity (> 95%). CairScotland (2010) report 
that ‘Bubbles’ was originally sold in capsules, but now more often in 1g 
bags. Reports suggest varying prices: around £10-15/g if purchased from 
‘headshops’, clubs or dealers (Druglink, 2010; Linell, 2010).   
 
4.6. Self-reported dosages range from 5 mg or less (for MDPV) to 200 mg or 
more (for mephedrone), with some mephedrone users reporting ‘re-dosing’ 
(bingeing) to prolong the euphoric experience, leading to 1-2g being 
consumed in a session. The cathinones are sometimes used in 
conjunction with alcohol or controlled substances; co-abused substances 
include cocaine, cannabis, ketamine and MDMA. Studies of polysubstance 
use with the cathinones are not available, however, it should be noted that 
polydrug use is increasingly a feature of UK illegal consumption patterns 
more generally.   
 
4.7. The reason for the apparent emergence and sudden increase in 
mephedrone use in the UK in 2009 is unclear. However, interviews with 
users and community workers (Newcombe, 2010; Measham et al., 2010, 
NME, 2010) suggest that the unavailability and/or low purity of cocaine 
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and MDMA in 2009 (Hand and Rishiraj, 2009) have contributed to the 
increase in mephedrone use. In addition, the cathinones are presently a 
legal alternative to other drugs and are widely available from internet 
websites.  
 
4.8. Mephedrone powder may be snorted (insufflated) (sometimes by 
keying6 – approximately 5-8 keys per gram (Linell, 2010)). The drug may 
also be swallowed – often after wrapping in tissue paper (bombing or 
dabbing) or, more rarely, injected (CairScotland, 2010; Linell, 2010; 
McVean, 2009; Measham et al., 2010).  
 
4.9. Reports from users presenting at hospital A&E units are that 
mephedrone is taken in staggered doses (Wood pers. comm.).  
 
4.10. Emergent research with mephedrone users suggests that they may 
appear to develop tolerance quickly and as a consequence tend to 
consume higher doses more frequently.  
 
4.11. Evidence from the Bailiwick of Guernsey Customs report an increase 
in the prevalence of mephedrone from seizures and this has superseded 
the seizures of ‘Toot’ (identified predominantly as Butylone and methylone) 
(McVean, 2009 and 2010). It is reported that mephedrone and ‘Toot’ are 
being injected by users and has become popular among users of heroin 
(McVean, 2009 and 2010).  
 
Prevalence and reported data 
4.12. There are little published data on the prevalence of the cathinones; most 
available data are from self reported surveys of particular demographics.  
 
4.13. Since many of the cathinones are not controlled, they are not included in 
the ‘stimulant’ group of substances in the British Crime Survey (BCS). 
However, we understand that the BCS will now include a specific question 
on mephedrone – interim data should be available to the ACMD after 6 
months of the question becoming part of the survey. 
  
4.14. The Mixmag survey (Winstock, 2010) is a cross sectional, self reported, 
self nominating, survey of over 2,000 UK individuals using the online 
website “Don’t Stay In” for the dance magazine Mixmag7. The most recent 
survey included a question on mephedrone. Of self reported drug use, 
mephedrone was the fourth most commonly used drug in the last month 
(Cannabis (any), ecstasy (any) and cocaine powder ranked higher in terms 
of % use in the last month). The survey data show that 41.7% of 
respondents indicated they had ever used mephedrone, 33.6% in the 
previous month. These data suggest that the use of mephedrone is a new 
phenomenon since lifetime and past month prevalence is so similar in this 
survey. The synthetic cathinone methylone had been tried by 7.5% of 
respondents in the last month and 10.8% in their lifetime. Also other 
                                                 
6 Keying is the activity by which a user dips a key into a bag of the powdered drug and then 
insufflates (snorts) off the key.   
7 The Mixmag survey was led by King’s College London.  
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surveys of drug use show no reported mephedrone use amongst similar 
groups of young adults surveyed in bars and clubs in 2004-8 (Measham 
and Moore, 2009).  
 
4.15. Data from the National Poisons Information Service (NPIS) show that 
telephone inquiries and TOXBASE8 accesses relating to cathinones 
increased sharply over the latter part of 2009 into 2010 (Thomas, 2010). 
NPIS enquiries more commonly involved males (2:1 sex ratio) and fitted 
an age profile similar to those taking MDMA with the greater proportion 
being in the 10-19 and 20-29 age groups, compared to cocaine which has 
a greater proportion of enquiries concerning the 20-29 and 30-39 age 
groups. 
 
4.16. The most up to date information regarding visits to the FRANK website 
relating to the cathinones page are presented in Table 3. The number of 
visits has more than doubled in the past six months and has shown a 
month on month increase since September 2009 when the page was first 
published. This is mirrored by similar increases in calls to the talk to 
FRANK helpline.   
 
Table 3. Visits to selected pages of the FRANK website9 between September 
2009 and February 2010*.  
 
 
FRANK 
website 
visits Cathinones 
% of 
visits Cannabis
% of 
visits Cocaine
% of 
visits Ecstasy 
% of 
visits 
Sept-09 (page 
published 
18/09/09) 255,765 9,366 3.7% 58185 22.7% 36925 14.4% 22541 8.8% 
Oct-09 376,751 33,167 8.8% 72470 19.2% 47140 12.5% 35745 9.5% 
Nov-09 444,069 47,954 10.8% 80246 18.1% 48489 10.9% 33167 7.5% 
Dec-09 314,236 54,299 17.3% 53141 16.9% 38570 12.3% 28691 9.1% 
Jan-10 358,537 66,236 18.5% 81986 22.9% 53736 15.0% 37910 10.6% 
Feb-10 378,576 80,969 21.4% 51319 13.6% 53736 14.2% 38028 10.0% 
*percentages are of total visits to individual drug webpages on FRANK website. 
 
4.17. ‘Google Insights for search’ is a tool that allows search volume 
patterns, specifically using the Google search engine, to be compared 
across regions, categories, time frames, and properties. ‘Google Insights 
for search’ has been used in this instance to determine the proportion of 
searches, using Google, to search for the word ‘mephedrone’ since 
January 2009 to March 2010 in the UK (England region only)10. It can be 
                                                 
8 TOXBASE is the primary clinical toxicology database of the National Poisons Information 
Service.  
9 See the following link for FRANK webpage on mephedrone: 
http://www.talktofrank.com/drugs.aspx?id=3597 
10 The data derived by Google insights does not reflect the actual number of searches carried 
out on Google. The data actually shows the number of searches for a particular term relative 
to the number of searches done on Google over time. The data is normalised, meaning that it 
is divided by a common variable to cancel out the effect of that variable on the data. Each 
point on the graph is divided by the highest point, or 100. When there is not enough data, 0 is 
shown. For example, if the highest peak is in March, this would be designated as 100. If the 
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seen from Figure 1 that there is a rising trend in the searches, although the 
month of March 2010 includes only partial data at this time. Please note 
that some months overlap due to the way in which the data is collated 
(weekly rather monthly).  
 
Figure 1. Relative number of searches on Google for the term ‘mephedrone’.  
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4.18. Data provided by the Forensic Science Service (FSS) of police seizures 
show that the cathinone derivatives account for only a small proportion of 
total drug seizures. Although the cathinones are not illegal they generally 
present as ‘white powders’ (predominantly mephedrone – 89% of 
cathinone seizures).  
                                                                                                                                            
next month the searches are half this figure, the second peak would be designated as 50, and 
so on. 
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5. Physical harms (toxicity, dependency and mental health) 
 
Acute toxicity  
5.1. Most data regarding the harms of the cathinones (mephedrone in 
particular) are self-reported and there are very few clinical data available.  
 
5.2. Wood et al., (2009) report the first case of sympathomimetic toxicity 
related to mephedrone (4-MMC) confirmed by toxicological screening 
where no other drugs or alcohol were detected.  
 
5.3. Data from Guys and St Thomas’ hospital toxicology (Dargan and 
Wood, pers. comm.) over the last year show that from a total of 1600-1800 
cases, of which 40% are due to recreational drugs, 25 of which presented 
with toxicity due to self reported mephedrone use (Table 4). Of these 25 
cases cases, 80% were male with a mean age of 28.5y (SD ± 8.0 y). 
Reported clinical symptoms are shown in Table 5, clinical examination 
data are shown in Table 6.  
 
Table 4. Cases of toxicity in individuals presenting due to self reported 
mephedrone use to Guys and St Thomas’ hospital 
 
 Number 
January – March 2009 2 
April – June 2009 0 
July – September 2009 8 
October – December 2009 5 
January 2010 – 22nd February 2010 10 
 
 
Table 5. Reported Clinical symptoms for cases of toxicity in individuals 
presenting due to self reported mephedrone use to Guys and St Thomas’ 
hospital 
 % presentations (n=25) 
Agitation 52 
Palpitations 20 
Seizure 12 
Vomiting 12 
Sweating 12 
Headache 4 
Discoloration of the skin 0 
Cool peripheries 0 
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Table 6. Clinical examination for cases of toxicity in individuals presenting due 
to self reported mephedrone use to Guys and St Thomas’ hospital 
 % presentations (n=25) 
Tachycardia >100bpm 48% 
Tachycardia >140bpm 16% 
Hypertension (>160mmHg) 16% 
GCS ≤ 8/15 16% 
Bruxism 4% 
Hyper-reflexia 4% 
 
5.4. The clinical management of those cases at Guys and St Thomas’ was 
that: 
• Four (16%) required benzodiazepines for management of agitation 
• Twenty (80%) discharged from ED/observation ward 
• Five admitted to hospital  
• Four to general medical ward 
• One to ICU (for other drug toxicity: GBL) 
 
5.5. Various user reports and clinical observations indicate that mephedrone 
abuse can cause a number of adverse side effects. Table 7 summarises 
self reported side effects of mephedrone in terms of increasing severity.  
 
Table 7. Self reported side effects of mephedrone 
Modest severity Moderate severity  Most severe 
Reduced appetite Insomnia Strong desire to re-
dose, craving to 
recapture initial euphoric 
rush  
Dry mouth Nausea (27%)* Uncomfortable changes 
in body temperature 
(sweating/chills) (67%)*  
Pupil dilation Trismus and Bruxism Increased blood 
pressure and heart rate, 
palpitations (43%)* 
Unusual body 
sensations 
Skin rashes serious vasoconstriction 
in extremities, cold or 
blue fingers (15%*)  
 
Change in body 
temperature regulation 
Nystagmus and dilated 
pupils 
high doses can cause 
hallucinations and 
psychosis  
 Pain and swelling in 
nose and throat, nose 
bleeds, sinusitis (when 
insufflated)  
 
 Impaired short term 
memory, poor 
concentration 
 
 Dizziness, light 
headidness, vertigo 
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(51%)* 
 Headache  
*Data from Mixmag survey n=>2,000 (Winstock, 2010) 
 
5.6. When taken in large quantities self-reported experiences by 
‘psychonaut’11 users described vivid hallucinations during 3 day binges 
of mephedrone (Linell, 2010). However, the quantities reportedly 
consumed are not likely to mirror those of most users. 
 
5.7. The ACMD has received anecdotal reports from members of the public 
that when taken in conjunction with other drugs e.g. amphetamines the 
effects can be quite marked and lead to personality changes, paranoia 
and sometimes violent episodes.  
 
5.8. Some of the adverse effects reported for methylone (Table 8) are similar 
to those reported for MDMA (ecstasy) (ACMD, 2009) 
 
Table 8. Self reported side effects of methylone  
 
Modest to moderate severity Most severe 
Increase in heart rate and blood 
pressure 
Insomnia 
General change in consciousness (as 
with most psychoactives) 
Hyperthermia and sweating 
Pupil dilation, can lead to blurred 
vision  
Dizziness, confusion  
Difficulty in focusing, restlessness Depersonalization, hallucinations, 
paranoia, fear (with high doses)  
Change in perception of time Unwanted life-changing spiritual 
experiences 
Slight increase in body temperature Gastrointestinal discomfort, nausea 
and vomiting 
Muscle tension and aching Skin rashes common 
Trismus and bruxism Hangover may include exhaustion, 
depression, disorientation, headach, 
amnesia.   
 
5.9. It is notable that several commonly reported side effects reflect the 
sympathomimetic actions of the cathinones. The NPIS is another 
important, independent source of information collected from telephone 
enquiries made by health professionals managing people presenting after 
mephedrone exposure and website visits. The most commonly reported 
clinical effects included tachycardia, palpitations, agitation, anxiety, 
palpitations and mydriasis. Chest pain, breathlessness, nausea, vomiting, 
headache, hypertension, confusion, hallucinations, peripheral 
vasoconstriction and convulsions have also been reported in some cases 
(Thomas, 2010). It is notable how closely the NPIS data match those 
provided from other sources.  
                                                 
11 A person who explores his own psyche, especially by taking psychedelic drugs. 
 Page 18 of 50  
 
5.10. Data from clinical examination confirms that tachycardia is a common 
symptom of mephedrone ingestion. Severe cases of cardiovascular 
toxicity or conditions such as hypopyrexia due to use of cathinones have 
not been reported (Dargan and Wood, pers. comm.). The majority of 
presentations have been recent and during the winter months, it is not 
known if the number of presentations due to conditions such as 
hypopyrexia will change during warmer weather.    
 
5.11. Users also report severe vasoconstriction of extremities, leading to 
bluing of fingers or hands. It is worth noting that hyperpyrexia and vascular 
collapse are among the most dangerous life-threatening side effects of 
amphetamine misuse12. Some of the acute adverse side effects induced 
by methylamphetamine include (ACMD, 2005): 
• Insomnia 
• Increased physical activity 
• Decreased appetite 
• Increased respiration 
• Hyperthermia 
• Increased heart rate and blood pressure 
• Irregular heart beat 
• Cardiovascular collapse and death (in overdose) 
• Confusion 
• Anxiety 
• Tremors 
 
Cases of death where cathinones have been implicated13
5.12. There have been at least 18 deaths in England where cathinones have 
been implicated. Currently, seven of these have provided positive results 
for the presence of mephedrone at post mortem. To date, in one case the 
coroner concluded that the death was “natural” and that an inquest was 
not required. The remaining cases are awaiting inquest. 
 
5.13. There have been at least seven deaths in Scotland where cathinones 
have been suspected. Of these, one has been confirmed as the result of 
the “adverse effects of methadone and mephedrone”. Another case is 
probable, but underlying health issues contributed to the death and it 
awaits formal confirmation by the relevant Procurator Fiscal. The presence 
of mephedrone has been confirmed in a third case.  
 
                                                 
12 see ACMD Reports on Methylamphetamine, and MDMA - 
http://drugs.homeoffice.gov.uk/drugs-laws/acmd/reports-research/index.html 
13 Data from the UK has been compiled by John Corkery on behalf of the National 
Programme on Substance Abuse Deaths from the following sources: Forensic Toxicology 
Service at St George’s, University of London; Forensic Science Service; Other Forensic 
Toxicology laboratories; Scottish Crime & Drug Enforcement Agency; Coroner’s offices; Drug 
& Alcohol Action Teams. In addition, some case details have been derived from media 
reports. Data is accurate at 26/03/2010. 
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5.14. One case on Guernsey has provided positive post mortem toxicology 
results for mephedrone and is awaiting inquest. 
 
5.15. One suspected case in Wales and a further case in Northern Ireland are 
awaiting toxicology and inquest.  
 
5.16. The UK number of cases are subject to several caveats: 
• Not all suspected cases may have been identified; 
• That mephedrone may have been involved in a death cannot be 
confirmed until the relevant coroner or Procurator Fiscal has 
concluded her/his inquest or other formal inquiry; and, 
• The presence of mephedrone in post mortem toxicology does not 
necessarily imply that it caused or contributed to a death.  
 
5.17. Mephedrone has been linked to the death of an 18-year old girl in 
Sweden (Gustaffsson and Escher, 2009). The report (December 2008) 
indicates that she had taken mephedrone and smoked cannabis. The 
woman was observed to first become sick and then unconscious. Forensic 
autopsy showed severe brain swelling, preceded by respiratory and 
circulatory arrest. No other sedatives, narcotics or alcohol were detected in 
the blood.   
 
Chronic toxicity  
5.18. There are so far no reports of the potential harmful effects of the long 
term use of mephedrone and related cathinones because the substances 
have only been used in recent months in the UK.   
 
Dependence  
5.19. Reports from a case study of mephedrone use (Linell, 2010) suggest 
that users can become regular users rapidly, although they are generally 
not in a ‘state of dependency’. However, this conclusion contrasts with the 
same report whereby users knew people who became daily users. Some 
users have reported developing cravings for mephedrone, methylone and 
MDPV after use. Arguing again by analogy with amphetamines, it is clear 
that the chronic use of amphetamines can lead to dependence, and a 
downward cycle of bingeing and periods of recovery associated with 
depression (ACMD, 2005), therefore it is likely that mephedrone use 
carries a similar risk of dependency.  
 
5.20. Dargan and Wood (2010) report a single case of dependency on 
mephedrone in Glasgow where the individual had been using the drug for 
18 months.   
 
5.21. Data are not available on the number of individuals in treatment services 
related to the cathinones. However, the evidence suggests that the 
number is likely to be very small at the time of writing.    
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6. Societal harms 
 
Prevalence  
6.1. The current prevalence of mephedrone and the related cathinones is 
not accurately known. Reports from drugs agencies, drug researchers, 
criminal justice, public health (Talk to FRANK) and education professionals 
suggest that mephedrone use appears to be very widespread and is 
growing. From emergence to current levels of usage, commentators have 
suggested that the rise in mephedrone use is unprecedented. Namely 
within a year it has risen from a very low baseline to become popular 
amongst adolescents and adults. 
 
Young people 
6.2. Media reports from the 8th March indicate that secondary school 
children were missing classes due to the use of the drug mephedrone 
causing sickness. The DCSF minister of State for Schools and Learners 
has written to schools. In the letter it makes clear that they do have the 
power to confiscate inappropriate items including a substance that they 
believe to be mephedrone (or any other drug, whatever its legal status); in 
line with the school’s behaviour policy and that such items do not need to 
be returned.  
 
6.3. Mephedrone is sold by online retailers for an average price of £10/g. 
Given that users take approximately one gram over the course of a 
session, this makes the drug relatively cheap compared with other 
intoxicants, as well as being more easily available than alcohol and 
cigarettes for under 18 year olds who have access to the internet or a high 
street ‘head shop’. 
 
6.4. There is some evidence that use has escalated following media 
reports. For example, Google Trends (which collates Google searches) 
shows that UK Google searches have increased from a very low base in 
the last twelve months (see paragraph 4.17), with peaks which coincide 
with media coverage of mephedrone use and deaths where mephedrone 
might be implicated. The most popular Google search term is for the words 
“buy mephedrone online”, with four of the top five search terms containing 
the words “buy” and “mephedrone”. Furthermore online mephedrone 
retailers have reported an increase in sales following media coverage (The 
Guardian, 2009) 
 
Anti-social behaviour / acquisitive crime  
6.5. The ACMD has been presented with two recent cases where 
mephedrone users have reported that their use was funded by acquisitive 
crime (robbery and burglary). At present there remains only limited 
evidence of a relationship between mephedrone and anti-social behaviour; 
mainly related to the open dealing and consumption of mephedrone. 
Notwithstanding the legal implications, the dealing in unspecified white 
powders for the purposes of intoxication can amount to a public nuisance 
with a detrimental impact on public confidence.   
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Organised crime 
6.6. There are indications that criminal groups are becoming involved in 
the supply of mephedrone to the public in the UK (SOCA, 2010). At 
present the mephedrone retail trade operates mainly through internet 
importation and distribution and ‘head shops’. However, there are reports 
of some UK drug suppliers selling mephedrone in dance clubs and at 
street level either as well as, or instead of cocaine and MDMA, due to 
mephedrone’s relatively low price, high purity and easy availability. 
Reports from Guernsey, where importation is currently banned (and prices 
are reported to be considerably higher), suggest that a street trade in 
mephedrone has developed. Reports from Guernsey customs officials 
note that supply is through illegal drug suppliers and incidences of 
violence have emerged associated with the street trade in mephedrone 
(McVean, 2010).  
 
Stockpiling  
6.7. It is reported that some users are planning to buy large quantities of 
mephedrone to ‘stockpile’ for future use and future sale should regulation 
be introduced (Measham et al., 2010; ACPO, pers. comm.). This could 
lead to an illegal supply of mephedrone coming on to the market should it 
be controlled under the Misuse of Drugs Act 1971.  
 
Consumption patterns   
6.8. It is of concern that there are reports that users of mephedrone have a 
tendency to re-dose (or ‘fiending’) and for some individuals the 
consumption of mephedrone is alone at home (Newcombe, 2010; Linnell, 
2010). Together these two features of mephedrone consumption patterns 
may expose users to increased risks such as overdose or cardiovascular 
problems.  
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7. Current controls 
 
Present UK controls  
7.1. Cathinone (Class C), methcathinone (Class B), diethylpropion (Class C) 
and pyrovalerone (Class C) are controlled under the Misuse of Drugs Act 
1971. However, other derivatives and analogues are not presently 
controlled (including mephedrone). 
 
7.2. Although paragraph 1(c) of Part 1 (Schedule 2) of the Misuse of Drugs 
Act 1971 offers some scope for the control of substances which are 
structurally related to the phenethylamine backbone, it is primarily 
concerned with ring-substituted amphetamine-like compounds. 
Specifically, no mention is made of the presence of any substituents (other 
than hydrogen) at the β-carbon of the phenethylamine backbone (recall 
that the cathinones all possess a β-ketone oxygen; see Figure 1).  
 
7.3. Irrespective of whether controls for the cathinones are implemented 
under the Misuse of Drugs Act 1971, the rapidity and easy availability of 
mephedrone and other cathinones (including websites set up so that 
vendors that can deliver to individual addresses) does raise the question 
of whether other legislation and regulation should be available.    
 
International Control 
7.4. Some of the substituted cathinones could conceivably be considered as 
being ‘structurally similar’ to cathinone and methcathinone, which are both 
already listed in Schedule 1 of the United Nations Convention on 
Psychotropic Substances 1971. It is therefore possible that some 
cathinones could be controlled through the implementation of analogue 
control where such control mechanisms exist.  
 
7.5. Denmark controls a number of cathinones, including mephedrone, 
methylone and MDPV. Mephedrone has been controlled in Sweden since 
December 2008; the Swedish authorities have indicated that they also 
intend to classify MDPV and butylone. Mephedrone is controlled (as a 
medicinal product) in Finland, and it is anticipated that it will shortly be 
controlled in Germany, since the German Federal Cabinet made a 
decision to subordinate a number of materials to the 
Betäubungsmittelgesetz in January 2009. Methylone is also controlled in 
the Netherlands. 
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8. Public Health 
8.1. The FRANK campaign (see also paragraph 4.16) provides information 
on the potential risks of taking cathinone compounds and there was also a 
recent campaign to highlight the dangers of ‘legal highs’ (‘Crazy Chemist’).  
 
8.2. Lifeline have produced an information leaflet14 that provides harm 
reduction advice specific to mephedrone and answers frequently asked 
questions from users or potential users (Lifeline, 2010). The ACMD is also 
aware that CairScotland have produced and distributed information leaflets 
warning of the dangers of these substances (CairScotland, 2010).  
 
8.3. Other than the above there is presently a limited amount of public health 
information regarding mephedrone and the cathinones. Although recent 
media profile has presented much apparent public health information it is 
not always credible or consistent.  
 
 
 
                                                 
14 The publication is available at: http://lifelinepublications.org/catalogue/methedrone-faqs 
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9. Conclusions and recommendations 
 
9.1. Although the current prevalence of mephedrone and related 
cathionones is relatively low in the UK, use appears to have grown rapidly 
in the past year. 
 
9.2. The ACMD would like to emphasise that mephedrone and the related 
cathinones are likely to be harmful to users and in tandem with control 
mechanisms there should be a credible and comprehensive public health 
campaign. The messages promulgated by FRANK provide a good basis 
upon which this should be built.  
 
Control and regulation  
9.3. The ACMD consider that the harms associated with mephedrone and 
the cathinones are commensurate with the amphetamines and therefore 
those substances in Class B; therefore the ACMD recommend that the 
cathinones be controlled as Class B substances under the Misuse of 
Drugs Act 1971.  
 
9.4. The ACMD recommend that, excluding the four compounds already 
controlled (see paragraph 2.2) and the API Bupropion, the cathinones 
should be controlled by a generic definition under the Misuse of Drugs Act 
1971 – see Annex A, p31, and in schedule 1 of the Misuse of Drugs 
Regulations 2001. 
 
9.5. The naphthyl analogue of pyrovalerone is now advertised on the 
Internet and is being retailed as “NRG-1”. The ACMD intend to review 
these substances and provide further advice at a later date.  
 
9.6. The ACMD recommend that the government implement appropriate 
additional controls and regulation of the cathinones (which would include 
mephedrone) through, for example: 
• Import controls 
• Serious Organised Crime Agency (SOCA)15 
 
9.7. The ACMD understand that to implement import controls is not 
administratively burdensome and would stop non-EU imports; where it is 
understood much of the importated cathinones originate from. The ACMD 
also believe that SOCA have a role in informing suppliers of the 
cathinones of the implementation of import controls, trading standards 
and, if implemented, forthcoming control under the Misuse of Drugs Act 
1971.  
 
9.8. The ACMD notes that the cathinones have no efficacy as plant fertiliser 
products or as bath salts and could be the subject of a prosecution under 
the Trade Descriptions legislation.       
                                                 
15 The involvement of SOCA is most relevant whilst the compounds are still licit. 
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Public Health 
9.9. Directors of public health in PCTs should be tasked with cascading 
information to raise awareness of the cathinones - symptoms of use and 
information on where to seek advice - among GP’s, A&E departments, 
medical directors / advisors and others as appropriate.  
 
9.10. The ACMD recommends that all agencies involved in the health, 
education and rehabilitation of young persons should disseminate 
information, in appropriate formats, as provided by the Department of 
Health and Home Office, as to the risks of using mephedrone (and 
associated compounds). We include in this Drug Action Teams (and 
equivalents e.g. DAATs in the Devolved Administrations), Childrens’ Trust 
Boards, Youth Offending Teams and Schools.   
 
9.11. We recommend that the FRANK webpages related to the cathinones 
are given due prominence and that supplementary educational material is 
easily available. The information provided should be credible and 
consistent. 
 
9.12. In relation to 9.9-9.11 it is important that the risks of mixing these drugs 
with other substances (including alcohol) are highlighted.  
 
9.13. The ACMD are presently identifying information streams to update 
ministers and provide information on both emerging drugs of misuse and 
emerging trends concerning established illegal drugs. The ACMD consider 
that this work will assist it in advising on ‘legal highs’ in the future. Among 
other measures, the continuing development of datasets from drug 
amnesty bins will contribute to providing an early warning of such 
emerging trends. 
 
9.14. Appropriate treatment advice and provision should be available to 
those who have developed cathinones-related problems of which health 
professionals and drugs service providers should be aware.  
 
Research 
9.15. Present forensic analytical testing of the cathinones is expensive and a 
process that can take some time. Currently, there is no simple drug field 
test available for cathinones. There is an urgent need to develop a simple 
and reliable field test. 
 
9.16.  For the purposes of identification of cathinone derivatives by forensic 
providers and pathology laboratories, and the development of drug field 
tests, there is an urgent need to develop and make available a library of 
reference standards. 
 
9.17. There is presently a lack of data concerning the involvement of the 
cathinones in drug-related deaths (DRDs). Therefore, we recommend that 
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the Ministry of Justice approach Her Majesty’s Coroners to include, in the 
case of suspected DRDs, tests for the cathinones.  
 
9.18. The ACMD welcome the collation of a joint report initiated by the 
European Drug Centre for Drugs and Drud Addiction (EMCDDA) in 
respect of mephedrone. However, we understand that this review will be 
limited in scope to mephedrone as an individual compound. The purpose 
of the present report is to review the broad spectrum of cathinone 
derivatives already encountered in the UK and to provide advice to 
ministers at the earliest opportunity. The ACMD will keep under 
consideration all emerging evidence including the EMCDDA’s forthcoming 
report(s) and will provide further advice to ministers accordingly. 
 
9.19. There is a need for more basic research to examine the similarities and 
differences between the cathinones and their amphetamine equivalents.  
 
9.20. We welcome the inclusion of a specific question on mephedrone in the 
British Crime Survey to develop the knowledge base on prevalence. The 
ACMD also recommends more social research to inform our 
understanding of drug trends, motivations for drug use, fluctuations in 
demand, and policy implications regarding deterrence, displacement and 
desistence.  
 
9.21. The ACMD would welcome the continuing collation of data sets 
concerning toxicity, clinical case reports and dependence liability collected 
from hospital admissions and treatment services.  
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Annex A. Recommendation for the generic control of the 
cathinone derivatives 
Scope of a generic definition 
The ACMD here set out recommendations on the range of compounds that 
should be included in a generic definition for the control of cathinone 
derivatives under the Misuse of Drugs Act 1971. 
 
It was proposed that the scope of compounds covered by generic control 
should be much wider than the 6 ring substituted compounds listed in Table 1 
(annex A) and wider than the 10 compounds reported to the EMCDDA since 
2006. 
 
The scope should include all cathinone derivatives that have been found in 
seizures and collected samples together with compounds that have not been 
encountered but have misuse potential. This includes cathinone derivatives 
with and without ring substituents and with side chains longer than those 
usually encountered in the phenethylamine drugs.   
 
The scope should also include any substances known or believed to be pro-
drugs, i.e. substances that are metabolised to a known active substance (for 
example GBL is converted in the body to GHB). 
 
The generic definition should not include those substances already controlled 
under the Misuse of Drugs Act, i.e. diethylpropion (Class C), cathinone (Class 
C), methcathinone (Class B) and pyrovalerone (Class C). Finally the definition 
should not include any substances, e.g. bupropion, that are ingredients of 
legitimate pharmaceutical products or that have other legitimate uses. 
 
The structure of cathinone derivatives is represented by the generalised 
structure below: 
N
R 1
R 3
R 2O
R 4
 
Figure 1: Generalised structure of cathinone derivatives 
 
where, 
 R1  =  single alkyl group [but not H] 
 R2  = H or alkyl 
 R3  =  H or alkyl or 
      [NR2R3] = pyrrolidino or phthalimido or other ring structure 
 R4  =  H (no substituents) or 
  =  one or more of alkyl, alkoxy, alkylenedioxy and halide whether or  
   not further substituted with an other univalent substituent 
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The phthalimido group has so far only been encountered in the compound 
α-phthalimidopropiophenone. This substance has been found in a capsule in 
combination with 2-fluoromethcathinone and in capsules containing a mixture 
with 4-methylmethcathinone, N-ethylcathinone, and caffeine. 
  
The reason for adding α-phthalimidopropiophenone is not clear. It may have 
been added deliberately, perhaps as a pro-drug for cathinone, but there is no 
information about its pharmacology or metabolism. This substance is also an 
intermediate in the synthesis of cathinone and N-alkyl derivatives of 
cathinone. It could therefore be present unintentionally as a residue of an 
intermediate, the product of a failed chemical synthesis, or even the miss-
labelling of an intermediate. 
 
In addition to compounds with the generalised structure in (Figure 1, Annex A) 
the phenyl ring can be replaced with a naphthyl ring (e.g. Figure 2, Annex A) 
or with a thiophene ring. The naphthyl analogue of pyrovalerone (Figure 2, 
Annex A) is available on the Internet and is being retailed as “NRG-1”. These 
compounds cannot easily be included in a generic definition for the cathinone 
derivatives having the generalised structure in Figure 1, Annex A, but they 
could be controlled as named substances or by one or more separate generic 
definitions. The ACMD intend to review these substances and provide further 
advice at a later date.  
 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH2
CH3  
Figure 2: Naphthyl analogue of pyrovalerone 
 
The systematic chemical name for the structure in Figure 2, Annex A is 1-(2-
naphthyl)-2-(1-pyrrolidinyl)-1-pentanone and alternative names include 
naphthylpyrovalerone, naphyrone and O-2482. 
 
Appendix I, of this Annex includes all the cathinone derivatives, with the 
general structure in Figure 1, Annex A, that have been encountered in 
seizures and collected samples, substances that are already controlled, 
ingredients of known pharmaceutical products, substances available via the 
Internet and substances that are listed in Wikipedia.  However, the market for 
cathinone derivatives is still evolving and new substances will continue to 
appear. 
 
Many cathinone derivatives are mentioned in patents for pharmaceutical 
applications but the only known non-controlled cathinone derivative with a 
marketing authorisation appears to be bupropion, an ingredient of ®Zyban. 
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Some cathinone derivatives are mentioned in patents for non-pharmaceutical 
applications.  
 
A structure-based search of the 12th Edition of the Merck Index (1996), carried 
out previously by Dr Les King, found no contentious compounds. 
 
Interestingly, a recent patent (WO PCT 2010006196) relating to water 
purification membranes mentions the compound in Figure 3 below, which is 
closely related to methylone (bk-MDMA). This compound would be included 
within a generic definition since the term methylenedioxy can have two 
meanings. However, compounds analogous to those in Figure 3, Annex A are 
unlikely to have any commercial uses. 
C
CH
N
H
CH3
O
CH3
O
O
CH2  
Figure 3: 3,4-methylenedioxy-N-methyl-β-keto-amphetamine 
 
Structure Activity Relationships 
Cathinone derivatives have a range of effects (e.g. stimulant, empathogen 
and antidepressant).  
 
The cathinone derivatives without ring substituents (e.g. diethylpropion, 
methcathinone, buphedrone, N,N-dimethylcathinone) are mostly stimulants. 
 
Most of the cathinone derivatives encountered as legal highs are ring 
substituted compounds with a secondary amino group (R2 = methyl or ethyl 
and R3 = hydrogen) or with a cyclic amino group (NR2R3 = pyrrolidino group or 
phthalimido group).  These substances are primarily stimulants, with varying 
degrees of empathogenic effects (i.e. similar in effects to MDMA).  Ring 
substituents (R4) have included alkyl, alkoxy, methylenedioxy and halide. 
 
The side chain substituent (R1) has mostly been a single alkyl group.  
However there are examples with allyl (an alkenyl) and propargyl (an alkynyl) 
groups and also examples with a second alkyl group attached to the same 
carbon atom as R1, but these compounds are not within the proposed scope. 
 
No haloalkyl substituents (e.g. trifluoromethyl –CF3  as found in piperazine 
derivatives) in the ring (R4) or on the side chain (R1) have been encountered 
or reported in the literature. However, replacement of the ring methyl group, 
as in mephredrone, with a trifluoromethyl group is likely to produce 
substances with similar activities. It is recommended therefore that haloalkyl 
substituents be included in the generic definition for ring substituents. 
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Cathinone derivatives with a primary amino group (i.e. no N-alkyl substituents) 
are rarely encountered, possibly because of their instability. There are only 
two known examples, bk-MDA (known to substitute for MDMA in rats) and 
cathinone (a stimulant).  
 
The NR2R3 amino groups reported in the scientific literature have included 
alkylamino (R2 = alkyl, R3 = H), dialkylamino (R2 =alkyl, R3 = alkyl), the cyclic 
pyrrolidino group and a large number of other cyclic amines.  However, for the 
pyrovalerone analogues an increase in size of the nitrogen containing ring 
from a five-membered pyrrolidine ring to a six-membered piperidine ring 
resulted in a substantial loss in binding potency.  There are also examples of 
N-allyl, N-propargyl and N-cycloalkyl substituents. 
 
The anti-depressant drug bupropion has a tertiary-butyl group on the nitrogen 
atom and several other substances investigated for their potential as smoking 
cessation drugs also have a bulky alkyl group on the nitrogen atom, e.g. 
tertiary-butyl, iso-propyl or cycloalkyl, or the alkyl amino group is replaced by 
a cyclic piperidino group (a cyclic amino group with 6 membered ring). 
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Salts, stereoisomers, esters and ethers 
Cathinone derivatives with the generalised structure in Figure 1, Annex A, all 
have an asymmetric α-carbon atom giving rise to R and S stereoisomers. 
 
With the exception of the phthalimido derivatives, all cathinone derivatives 
have a basic nitrogen atom and can therefore form salts. 
 
There is no definition of esters and ethers in the Misuse of Drugs Act 1971, 
but from a chemical perspective esters usually only applies to derivatives of 
acids with a hydroxyl group, and derivatives of alcohols and phenols.  
Likewise ethers usually only applies to derivatives of alcohols and phenols. 
On this basis the cathinone derivatives would not form esters or ethers. 
 
However, keto compounds, R1R2C=O, can form ketals, R1R2C(OR’)2, which 
arguably might be described as a special form of an ether.  Ketals of 
cathinone derivatives have been discussed on drug forums in the context of a 
pro-drug and are mentioned in the scientific literature, usually as a means of 
protecting the keto group during chemical syntheses. 
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Generic definition for the control of cathinone derivatives 
 
The ACMD have considered a number of options for the control of cathinone 
derivatives, including listing of named substances, several generic definitions 
and combinations of these approaches. 
 
Taking into account the ACMD’s consideration of the scope, together with 
structure activity relationships and prevalence of known cathinone derivatives, 
the following generic definition is recommended: 
 
Any compound (not being bupropion or a substance for the time being 
specified in paragraph 2.2) structurally derived from 2-amino-1-phenyl-1-
propanone by modification in any of the following ways, that is to say, 
(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, 
alkylenedioxy, haloalkyl or halide substituents, whether or not 
further substituted in the phenyl ring by one or more other univalent 
substituents; 
(ii) by substitution at the 3-position with an alkyl substituent; 
(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or 
by inclusion of the nitrogen atom in a cyclic structure. 
 
Notes 
• the parent compound is cathinone 
• “any” is taken to mean one or more 
 
Comments 
This is a definition that includes all permutations for the three substitution 
areas, i.e. in the ring (R4), in the side chain (R1) and on the nitrogen (NR2R3). 
• All the cathinone derivatives would be in the same Class which would 
result in some anomalies for compounds already controlled. 
• Includes all the compounds in Appendix 1. 
• Includes primary amines without ring substituents (no known examples, 
except cathinone which is not included within the scope of this definition). 
• Includes ring substituted primary amines (bk-MDA is the only example). 
• The term “cyclic structure” has a very wide scope (e.g. all ring sizes, all 
heterocyclic nitrogen compounds and structures with ring substituents).  
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Appendix 1 
 
Names R1 R2 R3 R4 Structure 
Cathinone 
(Class C) 
beta-keto-amphetamine 
 
Note: only encountered in Khat 
although it has been encountered 
as the pro-drug, 
α-phthalimidopropiophenone (see 
below) 
Me H H H 
C
CH
NH2
CH3
O
 
α-phthalimidopropiophenone 
 
Note: found in products from the 
Internet 
Me NR
2R3 = 
phthalimide H C
CH
N
CH3
O
O
O
 
Methcathinone 
(Class B) 
Ephedrone 
α-methylaminopropiophenone 
Me Me H H 
C
CH
N
H
CH3
O
CH3
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Names R1 R2 R3 R4 Structure 
N,N-Dimethylcathinone 
Metamfepramone 
Dimethylpropion 
 
Note: encountered in seizures 
Me Me Me H 
C
CH
N
CH3
O
CH3
CH3
 
Ethcathinone 
Ethylpropion 
N-ethylcathinone 
2-ethylamino-propiophenone 
Sub Coca II 
 
Note: encountered in seizures 
Me Et H H 
C
CH
N
H
CH3
O
CH2
CH3
 
Diethylpropion (Class C) 
Diethylcathinone 
Amfepramone 
Me Et Et H C CH
N
CH3
O
CH2
CH3
CH2
CH3
 
α-Pyrrolidinopropiophenone 
α-PPP 
 
Note: encountered in Germany 
Me NR
2R3 = 
Pyrrolidinyl H 
C
CH
N
CH3
O
CH2
CH2
CH2CH2
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Names R1 R2 R3 R4 Structure 
2-methylamino-1-phenylbutan-1-
one 
Buphedrone 
 
Note: no seizures reported to 
EMCDDA but is available via the 
Internet and user reports are on 
drug forums. 
Et Me H H 
C
CH
N
H
CH2
O
CH3
CH3  
α-Pyrrolidinobutiophenone 
α-PBP 
 
Note: no seizure or user reports 
but listed on Wikipedia and in a 
patent 
Et NR
2R3 = 
Pyrrolidinyl H 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH3  
α-Pyrrolidinovalerophenone 
α-PVP 
α-Pyrrolidinopentiophenone 
 
Note: No seizures reported to 
EMCDDA, but metabolism study 
by Germany, as a result of 2 
seizures, in Germany and 
Netherlands. 
n-Pr NR
2R3 = 
Pyrrolidinyl H 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH2
CH3  
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Names R1 R2 R3 R4 Structure 
4-Methylmethcathinone 
4-MMC 
Mephedrone 
Sub Coca I 
 
Note: most frequently encountered 
cathinone derivative 
Me Me H 4-Me 
C
CH
N
H
CH3
O
CH3
CH3  
4’-methyl-α-
pyrrolidinopropiophenone 
MPPP 
 
Note: seizure report from Germany 
Me NR
2R3 = 
Pyrrolidinyl 
4-Me 
 
C
CH
N
CH3
O
CH2
CH2
CH2CH2
CH3  
4’-methyl-α-
pyrrolidinobutiophenone 
MPBP 
 
Note: seizure report from Germany 
Et NR
2R3 = 
Pyrrolidinyl 4-Me 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH3 CH3  
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Names R1 R2 R3 R4 Structure 
Pyrovalerone 
(Class C) 
 
n-Pr NR
2R3 = 
Pyrrolidinyl 4-Me 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH3 CH2
CH3  
4’-methyl-α-
pyrrolidinohexiophenone 
MPHP 
 
Note: seizure report from Germany 
n-Bu NR
2R3 = 
Pyrrolidinyl 4-Me 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
CH3 CH2
CH2
CH3  
4-methoxymethcathinone 
PMMC 
Methedrone 
bk-PMMA 
 
Note: encountered in seizures 
Me Me H 4-MeO 
C
CH
N
H
CH3
O
CH3
CH3O  
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Names R1 R2 R3 R4 Structure 
4’-Methoxy-α-
pyrrolidinopropiophenone 
MOPPP 
 
Note: seizure report from Germany 
Me NR
2R3 = 
Pyrrolidinyl 4-MeO 
C
CH
N
CH3
O
CH2
CH2
CH2CH2
CH3O  
Bupropion 
(Zyban – medicinal product in UK) 
 
Note: To be excluded from control. 
No reports of abuse 
Me t-Bu H 3-Cl 
C
CH
N
H
CH3
O
C
Cl
CH3
CH3
CH3
 
4-Fluoromethcathinone 
Flephedrone 
4FMC 
 
Note: encountered in seizures. The 
3-fluoro and 2-fluoro isomers have 
also been found in products from 
the Internet. 
Me Me H 4-F (also 2-F and 3-F) 
C
CH
N
H
CH3
O
CH3
F  
3,4-Methylenedioxymethcathinone 
Methylone 
bk-MDMA 
 
Note: encountered in seizures 
Me Me H 3,4-methylenedioxy 
C
CH
N
H
CH3
O
CH3
O
CH2
O  
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Names R1 R2 R3 R4 Structure 
3,4-methylenedioxyethcathinine 
Ethylone 
bk-MDEA 
 
Note: encountered in seizures 
Me Et H 3,4-methylenedioxy 
C
CH
N
H
CH3
O
CH2
O
CH2
O
CH3
3’,4’-methylenedioxy-α-
pyrrolidinopropiophenone 
MDPPP 
 
Note: seizure reports from 
Germany and Denmark 
Me NR
2R3 = 
Pyrrolidinyl 3,4-methylenedioxy 
C
CH
N
CH3
O
CH2
CH2
CH2CH2
O
CH2
O  
β-keto-N-methyl-3,4-
benzodioxyolylbutanamine 
Butylone 
bk-MDBD 
 
Note: seizure reports from 
7 countries 
Et Me H 3,4-methylenedioxy 
C
CH
N
H
CH2
O
CH2
O
CH2
O
CH3
CH3
3’,4’-Methylenedioxy-α-
pyrrolidinobutiophenone 
 
Note: no seizure reports, but 
mentioned in Wikipedia and in 
patent 
Et NR
2R3 = 
Pyrrolidinyl 3,4-methylenedioxy 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
O
CH2
O CH3  
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 44 
Names R1 R2 R3 R4 Structure 
Pentylone 
β-Keto-
methylbenzodioxolylpentanamine  
bk-Methyl-K 
bk-MBDP 
 
Note: no seizure reports, but 
mentioned in Wikipedia and in 
patent 
n-Pr Me H 3,4-methylenedioxy 
C
CH
NH
CH2
O
O
CH2
O CH2
CH3
CH3
 
Methylenedioxypyrovalerone 
MDPV 
 
Note: encountered in seizures 
n-Pr NR
2R3 = 
Pyrrolidinyl 3,4-methylenedioxy 
C
CH
N
CH2
O
CH2
CH2
CH2CH2
O
CH2
O CH2
CH3  
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Annex B. Members of the Advisory Council on the Misuse of 
Drugs 
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Professor Leslie Iversen 
(ACMD Chair) 
 
Sector 
 
Professor of Pharmacology, Oxford University 
 
Lord Victor Adebowale Chief Executive, Turning Point   
 
Dr Dima Abdulrahim 
 
Briefings Manager, National Treatment 
Association 
 
Mrs Gillian Arr-Jones  
 
 
Chief Pharmacist for the Care Quality 
Commission 
Mr Martin Barnes Chief Executive, Drugscope 
 
Dr Margaret Birtwistle Specialist General Practitioner, Senior Tutor – 
Education and Training Unit, St George’s 
Hospital and Forensic Medical Examiner  
 
Commander Simon Bray 
 
Commander, Metropolitan Police 
Mr Eric Carlin 
 
Former Chief Executive of Mentor 
Ms Carmel Clancy Principal Lecturer for Mental Health and 
Addiction, Middlesex University  
 
Professor Ilana Crome Professor of Addiction Psychiatry, Keele 
University 
 
Ms Robyn Doran Mental Health Nurse and Director of Operations, 
North-West London Mental Health Trust 
 
Professor Simon Gibbons  
 
 
 
Professor of Phytochemistry (natural product 
chemistry), School of Pharmacy, University of 
London 
Mr Patrick Hargreaves Advisor for Drugs and Alcohol, Durham County 
Council Education Department 
 
Ms Caroline Healy National Adviser for the commissioning of 
mental health services for children in secure 
settings, Department of Health 
 
Dr Matthew Hickman  Reader in Public Health and Epidemiology, 
Department of Social Medicine, University of  
Bristol 
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Dr Fiona Measham Senior Lecturer in Criminology, University of 
Lancaster 
 
Mr David Liddell 
 
Director, Scottish Drugs Forum 
Mr Hew Mathewson CBE  
 
 
Dentist and former President and Chair of the 
General Dental Council (2002 to 2009) 
Mr Trevor Pearce Director of Enforcement, Serious Organised 
Crime Agency 
 
District Judge Justin 
Phillips 
 
District Judge, Drugs Court London 
Mr Richard Phillips 
 
Independent Consultant, Phoenix Futures 
DCC Howard Roberts Deputy Chief Constable, Nottinghamshire Police 
 
Dr Mary Rowlands Consultant Psychiatrist in Substance Misuse, 
Exeter 
 
Ms Monique Tomlinson Freelance Consultant in Drugs Misuse 
Mr Arthur Wing Assistant Chief Officer – Sussex Probation Area 
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Annex C. Organisations and affiliated individuals submitting 
evidence concerning the cathinones to the Advisory Council 
on the Misuse of Drugs, February 22nd 2010. 
 
Association of Chief Police Officers 
 
 
Association of Chief Police Officers in 
Scotland 
 
 
Avon and Somerset Constabulary  
 
Bunt, P 
Cair, Scotland 
 
Burns, M 
Centre for Public Health, Liverpool John 
Moore’s University  
 
 
Customs & Excise, Immigration and 
Nationality Service - Guernsey 
 
McVean, C 
Drugscope 
 
 
Forensic Science Service 
 
White, M 
FRANK Department of Health / Home 
Office 
Guernsey customs and Excise 
 
McVean, C 
Guys and St Thomas’ Hospital, London 
 
Dargan, P, Wood, D 
Isle of Man  
 
Department of Home Affairs 
Key Forensic  
 
 
Kings College London 
 
Winstock, A 
Lancaster University 
 
Measham, F 
LGC Forensics 
 
Treble, R 
Lifeline Linell, M 
 
National Poisons Information Service Thomas, S  
Scientifics Ltd 
 
 
Serious Organised Crime Agency  
St Georges University London, National 
Programme on Substance Abuse Deaths 
 
Corkery, J 
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TICTAC Communications 
 
Ramsey, J 
UK Border Agency 
 
Deller, P 
  
Members of the public  
  
The ACMD is very grateful to all those who have submitted evidence and lent 
their expertise to our understanding of the cathinones. 
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Annex D. Letter from the Advisory Council on the Misuse of 
Drugs to the Home Secretary.  
 
ACMD 
Advisory Council on the Misuse of Drugs 
Secretary: Will Reynolds 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
Tel: 020 7035 0454  
ACMD@homeoffice.gsi.gov.uk
 
Rt Hon Alan Johnson 
2 Marsham Street 
London  
SW1P 4DF 
22nd December 2009 
 
Dear Home Secretary,  
 
Re: ACMD consideration of mephedrone (and related cathinones) 
 
The ACMD wrote to you in March to explain that it would be pleased to 
accede to the Government’s priorities that your predecessor set out in her 
letter of 13 March 2009. Concerning the issue of ‘legal highs’ the ACMD has 
provided advice on the synthetic cannabinoid receptor agonists (Spice), 1-
benzylpiperazine, GBL and 1,4-BD all of which we note will be controlled in 
the legislation on the 23rd December. In the ACMD’s letter of 30 September 
2009 it was explained that we would next provide you with advice on the 
cathinones.  
 
Despite the difficulties of the last 2 months the ACMD is committed to 
providing you with advice on the cathinones. Although attention has focused 
on mephedrone, five other synthetic psychoactive cathinone derivatives are 
also widely available.  The ACMD explained in a previous letter to you that it 
has concerns about the apparent prevalence and potential harms of these 
compounds. Much has been made of these compounds in the media over 
recent weeks; we find it of concern that this may have had the consequence 
of bringing such drugs to the attention of a wider demographic sooner than 
may have been the case.  
 
The ACMD understand that mephedrone, amongst other cathinones, is being 
marketed as a variety of apparently ‘benign’ products e.g. bath salts or plant 
food. Whilst the potential harms of these drugs are not yet fully known, it is 
apparent that the selling of such unregulated preparations in a form that they 
are clearly unintended for could have serious public health implications.   
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The ACMD is mindful that, after recent events, our statutory membership 
requirements need to be fulfilled before providing formal advice, according to 
the requirements of the Misuse of Drugs Act 1971. However, the ACMD would 
like to assure you that it will seek to provide you with such advice at the 
earliest possible opportunity on this important issue.   
 
I would be willing to discuss the issue of the cathinones and, more broadly, 
new psychoactive substances (‘legal highs’) and the timing of advice with you.  
 
Yours sincerely, 
 
 
Professor Les Iversen 
(on behalf of the ACMD) 
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